Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DDO | Q99489 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NEK2 | P51955 | 3/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15587736 | 0.81 | AAK1 (0.35) | ALDH1A1 | |
| SCHEMBL15902113 | 0.80 | MAPT (0.37) | ALDH1A1KDM4ELMNAKMT2AHTT | |
| SCHEMBL15545613 | 0.79 | GABRP (0.39) | ALDH1A1KDM4CKDM4ELMNAMEN1 | |
| SCHEMBL15545493 | 0.77 | ALDH1A1 (0.45) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL15545495 | 0.77 | ALDH1A1 (0.45) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL15545025 | 0.75 | MAPT (0.36) | ALDH1A1KDM4CKDM4ELMNAMEN1 | |
| SCHEMBL20918389 | 0.73 | ALDH1A1 (0.39) | ALDH1A1KDM4CKDM4ELMNAMEN1 | |
| SCHEMBL15770749 | 0.72 | ALDH1A1 (0.36) | ALDH1A1KDM4CKDM4ELMNAHTT | |
| SCHEMBL15545335 | 0.70 | L3MBTL1 (0.39) | ALDH1A1KDM4CKDM4ELMNAKMT2A | |
| SCHEMBL29158125 | 0.70 | AGBL2 (0.44) | ALDH1A1KDM4CKDM4EGAACA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316028-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-06-11 | — | — | US | disclosed |
| US-20180370961-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-12-27 | — | — | US | disclosed |
| US-9850237-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-12-26 | — | — | US | disclosed |
| US-20170121320-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-05-04 | — | — | US | disclosed |
| EP-2870144-B1 | OREXIN RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-9555044-B2 | Orexin receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-01-31 | — | — | US | disclosed |
| US-20160213678-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2016-07-28 | — | — | US | disclosed |
| EP-2870144-A1 | OREXIN RECEPTOR ANTAGONISTS | Heptares Therapeutics Limited (GB) | 2015-05-13 | — | — | EP | disclosed |
| US-20150126498-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-05-07 | — | — | US | disclosed |
| WO-2014006402-A1 | OREXIN RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121320-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | ALDH1A1 3165/4885KDM4C 2074/4885KDM4E 1025/4885 |
| US-10316028-B2 | Orexin receptor antagonists | HCRTR2, HCRTR1, NPY4R | ALDH1A1 3165/4885KDM4C 2074/4885KDM4E 1025/4885 |
| US-20180370961-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | ALDH1A1 3165/4885KDM4C 2074/4885KDM4E 1025/4885 |
| US-20150126498-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | ALDH1A1 3165/4885KDM4C 2074/4885KDM4E 1025/4885 |
| US-20160213678-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | ALDH1A1 3165/4885KDM4C 2074/4885KDM4E 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.